Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Intracerebral hemorrhage is the least treatable form of stroke. We performed this phase 3 trial to confirm a previous study in which recombinant activated factor VII (rFVIIa) reduced growth of the hematoma and improved survival and functional outcomes. METHODS: We randomly assigned 841 patients with intracerebral hemorrhage to receive placebo (268 patients), 20 microg of rFVIIa per kilogram of body weight (276 patients), or 80 microg of rFVIIa per kilogram (297 patients) within 4 hours after the onset of stroke. The primary end point was poor outcome, defined as severe disability or death according to the modified Rankin scale 90 days after the stroke. RESULTS: Treatment with 80 microg of rFVIIa per kilogram resulted in a significant reduction in growth in volume of the hemorrhage. The mean estimated increase in volume of the intracerebral hemorrhage at 24 hours was 26% in the placebo group, as compared with 18% in the group receiving 20 microg of rFVIIa per kilogram (P=0.09) and 11% in the group receiving 80 microg (P<0.001). The growth in volume of intracerebral hemorrhage was reduced by 2.6 ml (95% confidence interval [CI], -0.3 to 5.5; P=0.08) in the group receiving 20 microg of rFVIIa per kilogram and by 3.8 ml (95% CI, 0.9 to 6.7; P=0.009) in the group receiving 80 microg, as compared with the placebo group. Despite this reduction in bleeding, there was no significant difference among the three groups in the proportion of patients with poor clinical outcome (24% in the placebo group, 26% in the group receiving 20 microg of rFVIIa per kilogram, and 29% in the group receiving 80 microg). The overall frequency of thromboembolic serious adverse events was similar in the three groups; however, arterial events were more frequent in the group receiving 80 microg of rFVIIa than in the placebo group (9% vs. 4%, P=0.04). CONCLUSIONS: Hemostatic therapy with rFVIIa reduced growth of the hematoma but did not improve survival or functional outcome after intracerebral hemorrhage. (ClinicalTrials.gov number, NCT00127283 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
(1965) · PubMed · Cited by 14,925
ASSESSMENT OF COMA AND IMPAIRED CONSCIOUSNESS
Teasdale, G., & Jennett, B. (1974) · The Lancet · doi:10.1016/s0140-6736(74)91639-0 · Cited by 13,215
Functional evaluation : Barthel index
Mahonery, F. I. (1965) · Medical Entomology and Zoology · Cited by 12,762
Interobserver agreement for the assessment of handicap in stroke patients
van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988) · Stroke · doi:10.1161/01.str.19.5.604 · Cited by 6,512
Measurements of acute cerebral infarction: a clinical examination scale.
Brott, T., Adams, H. P., Olinger, C. P., Marler, J. R., Barsan, W. G., Biller, J., Spilker, J., Holleran, R., Eberle, R., & Hertzberg, V (1989) · Stroke · doi:10.1161/01.str.20.7.864 · Cited by 5,911
WILSON, J. T. L., PETTIGREW, L. E. L., & TEASDALE, G. M. (1998) · Journal of Neurotrauma · doi:10.1089/neu.1998.15.573 · Cited by 2,386
The ICH Score: A Simple, Reliable Grading Scale for Intracerebral Hemorrhage
Hemphill, J. C., Bonovich, D. C., Besmertis, L., Manley, G. T., & Johnston, S. C. (2001) · Stroke · doi:10.1161/01.str.32.4.891 · Cited by 2,196
Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality.
Broderick, J. P., Brott, T. G., Duldner, J. E., Tomsick, T., & Huster, G. (1993) · Stroke · doi:10.1161/01.str.24.7.987 · Cited by 1,746
Self-citationEarly Hemorrhage Growth in Patients With Intracerebral Hemorrhage
Brott, T., Broderick, J., Kothari, R., Barsan, W., Tomsick, T., Sauerbeck, L., Spilker, J., Duldner, J., & Khoury, J. (1997) · Stroke · doi:10.1161/01.str.28.1.1 · Cited by 1,477
Self-citationHematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage
Davis, S. M., Broderick, J., Hennerici, M., Brun, N. C., Diringer, M. N., Mayer, S. A., Begtrup, K., & Steiner, T. (2006) · Neurology · doi:10.1212/01.wnl.0000208408.98482.99 · Cited by 1,168
Self-citation
Research works printed but not linked: 2
- Zimmerman RD, 2006, AJNR Am J Neuroradiol, 27, 666
- Mahoney FI, 1965, Md State Med J, 14, 61
Cited by
Items 701–800 of 1,000
Traitements des accidents vasculaires cérébraux en phase aiguë et prévention secondaire
Leys, D., & Cordonnier, C. (2009) · médecine/sciences · doi:10.1051/medsci/2009258-9733 · Cited by 13
“Malgré un essai de phase 2b prometteur [18], ce traitement n’a pas fait preuve d’efficacité lors d’un essai de phase 3 [19].”
BackgroundAcute Management of Hemostasis in Patients With Neurological Injury
Baharoglu, M. I., Brand, A., Koopman, M. M. W., Vermeulen, M., & Roos, Y. B. W. E. M. (2017) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2017.07.002 · Cited by 9
Marsh, K. L., Green, D., Raco, V., Papadopoulos, J., & Ahuja, T. (2020) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944720924255 · Cited by 9
Yang, J., Jing, J., Chen, S., Liu, X., Wang, J., Pan, C., & Tang, Z. (2024) · European journal of medical research · doi:10.1186/s40001-024-01816-5 · Cited by 9
“The randomized, double-blind, placebo-controlled FAST trial showed that rFVIIa significantly reduced the growth of the hematoma but failed to improve survival or functional outcome at 90 days [50].”
BackgroundP2Y12 inhibitor use predicts hematoma expansion in patients with intracerebral hemorrhage
Houskamp, E. J., Liu, Y., do Nascimento, J. S. P., Jahromi, B. S., Lindholm, P. F., Kwaan, H. C., & Naidech, A. M. (2024) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.52070 · Cited by 8
Mengel, A., Siokas, V., Buesink, R., Roesch, S., Laichinger, K., Ferizi, R., Dardiotis, E., Schwarz, P., Sartor‐Pfeiffer, J., Single, C., et al. (2024) · Brain Hemorrhages · doi:10.1016/j.hest.2024.06.001 · Cited by 8
Low Hemoglobin Causes Hematoma Expansion and Poor Intracerebral Hemorrhage Outcomes
Cottarelli, A., Mamoon, R., Ji, R., Mao, E., Boehme, A. K., Kumar, A., Song, S., Allegra, V., Sharma, S. V., Konofagou, E. E., et al. (2025) · Stroke · doi:10.1161/strokeaha.124.049499 · Cited by 10
Impact of Intraventricular Hemorrhage upon Intracerebral Hematoma Expansion
Moussouttas, M., Malhotra, R., Fernández-Salazar, L. I., Maltenfort, M., Holowecki, M., Delgado, J. R., Lawson, N., & Badjatia, N. (2010) · Neurocritical Care · doi:10.1007/s12028-010-9452-0 · Cited by 9
“Also excluded were patients <18-year-old, those enrolled in the Factor Seven for Acute Hemorrhagic Stroke Trial (FAST) [4], those undergoing surgical evacuation prior to the second CT, and those lacking a follow-up CT.”
Recombinant factor VIIa use in refractory ulcer bleeding in uremic patient
Wang, A.-Y., Yuan, A., Huang, C., Chang, W., Liang, P., Lin, T.-H., & Chen, S. (2011) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2011.05.010 · Cited by 8
Emerging haemostatic agents and patient blood management
Tanaka, K. A., & Kor, D. J. (2013) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2013.02.004 · Cited by 8
Zhao, D. X.-M., Radford, J., Tamis‐Holland, J. E., Tommaso, C. L., Tracy, C. M., Linderbaum, J. A., Morrow, D. A., Newby, L. K., Ornato, J. P., Fesmire, F. M., et al. (2014) · Cited by 8
Acosta, J., Brown, S. C., & Falcone, G. J. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00837-2 · Cited by 8
Shahrestani, S., Strickland, B. A., Bakhsheshian, J., Mack, W. J., Toga, A. W., Sanossian, N., Tai, Y., & Zada, G. (2021) · Neurosurgical FOCUS · doi:10.3171/2021.4.focus21121 · Cited by 9
Morotti, A., Busto, G., Boulouis, G., Scola, E., Padovani, A., Casetta, I., & Fainardi, E. (2022) · European Radiology · doi:10.1007/s00330-022-08987-x · Cited by 10
“Conversely, a more restrictive approach with higher specificity may be desired when studying therapies with potentially serious thrombotic side effects such as recombinant factor VII administration [27].”
BackgroundYuan, Z., Wei, Q., Chen, Z., Xing, H., Zhang, T., & Li, Z. (2023) · Neurosurgical Review · doi:10.1007/s10143-023-02015-2 · Cited by 8
“Conservative treatment is still widely used, but the administration of tranexamic acid and the use of recombinant activated factor VII have failed to improve functional outcome [16, 17].”
Supporting Post-Stroke Language and Cognition with Pharmacotherapy: Tools for Each Phase of Care
Stockbridge, M. D., & Keser, Z. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01273-3 · Cited by 10
“Based on the preliminary positive evidence from smaller scale studies, recombinant factor VIIa (rVIIa) was tested in patients with intracerebral hemorrhage within the first 4 h in the phase III trial [57].”
BackgroundManagement of Spontaneous Intracerebral Hemorrhage
Naval, N. S., Nyquist, P., & Carhuapoma, J. R. (2008) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2008.07.014 · Cited by 9
Management of Acquired Bleeding Problems in Cancer Patients
DeLoughery, T. G. (2009) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2009.04.004 · Cited by 8
Yaghi, S. R., Haggiagi, A. M., Sherzai, A. Z., Marshall, R. S., & Agarwal, S. (2015) · Clinics and Practice · doi:10.4081/cp.2015.756 · Cited by 8
Barras, C. D., Asadi, H., Phal, P. M., Tress, B. M., Davis, S. M., & Desmond, P. M. (2016) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.12491 · Cited by 8
“including the inclusion of patients without evidence of active bleeding.(2,3) As a result, three trials of haemostatic agents based upon imaging-based treatment randomisation according to CTA spot sign status are in progress, targeting patients with imaging evidence of dynamic haemorrhage,(4) two in North America (STO…”
BackgroundSelf-citationZhang, L., Tao, W., Feng, H., & Chen, Y. (2017) · Stem Cells International · doi:10.1155/2017/2412890 · Cited by 9
An Update on Neurocritical Care for the Patient With Kidney Disease
Hirsch, K. G., & Josephson, S. A. (2012) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2012.09.003 · Cited by 8
Ashley, W. W., Charbel, F. T., & Amin‐Hanjani, S. (2008) · Neurologic Clinics · doi:10.1016/j.ncl.2008.06.006 · Cited by 8
Critical Care of the Patient with Acute Stroke
Sykora, M., Schönenberger, S., & Bösel, J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-29544-4.00054-2 · Cited by 8
Recent Advances in the Acute Management of Intracerebral Hemorrhage
Burns, J. D., Fisher, J. L., & Cervantes-Arslanian, A. M. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.06.009 · Cited by 8
Intraoperative Blood and Coagulation Factor Replacement During Neurosurgery
Zhou, J. J., Chen, T., & Nakaji, P. (2018) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2018.06.006 · Cited by 8
Pooled analysis suggests benefit of catheter-based hematoma removal for intracerebral hemorrhage
Mandava, P., Murthy, S. B., Shah, N., Samson, Y., Kimmel, M., & Kent, T. A. (2019) · Neurology · doi:10.1212/wnl.0000000000007269 · Cited by 8
“Trials of hemostatic agents An early phase trial(4) tested 3 doses of recombinant factor VIIa (rFVIIa: O, P, Q) against a control arm (o) as a precursor to the Recombinant Factor VIIa in Acute Intracerebral Haemorrhage (FAST) trial.(5) All 3 treatment arms of the early phase trial(4) had lower NIHSS than the control a…”
MethodVariation in the use of recombinant activated factor VII in critical bleeding
Willis, C. D., Cameron, P. A., & Phillips, L. (2009) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2009.02044.x · Cited by 8
Fowler, R., Adhikari, N. K. J., Scales, D. C., Lee, W. L., & Rubenfeld, G. D. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200902-0207up · Cited by 8
“In contrast, promising results from a phase II randomized trial of recombinant activated factor VII for acute intracerebral hemorrhage were not confirmed in a phase III trial, which found slower hematoma growth but no effect on mortality or functional outcomes (178).”
ResultAnderson, C. S., Heeley, E. L., Heritier, S. R., Arima, H., Woodward, M., Lindley, R. I., Neal, B. C., Huang, Y., Wang, J., Parsons, M. W., et al. (2013) · International Journal of Stroke · doi:10.1111/ijs.12004 · Cited by 8
Self-citationReversing Oral Anticoagulation in Intracerebral Hemorrhage
Smith, W. S., & Hemphill, J. C. (2024) · New England Journal of Medicine · doi:10.1056/nejme2403726 · Cited by 8
Yu, W., & Alexander, M. J. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003408 · Cited by 8
“[18] A secondary analysis of the FAST data suggested that patients with age ≤ 70 years, ICH volume 60 mL, intraventricular hemorrhage (IVH) volume 5 mL, and onset-to-treatment time ≤ 2.5 h had almost 50% reduction in hematoma growth (7.3 ± 3.2 vs .”
InfluentialSafety Issues and Concerns for the Neurological Patient in the Emergency Department
Manno, E. M. (2008) · Neurocritical Care · doi:10.1007/s12028-008-9111-x · Cited by 7
Predicting hematoma expansion using machine learning: An exploratory analysis of the ATACH 2 trial
Kumar, A. R., Witsch, J., Frontera, J. A., Qureshi, A. I., Oermann, E. K., Yaghi, S. R., & Melmed, K. R. (2024) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2024.123048 · Cited by 7
Tran, A. T., Desser, D., Zeevi, T., Karam, G. A., Dierksen, F., Dell’Orco, A., Kniep, H. C., Hanning, U. M. P., Fiehler, J., Zietz, J., et al. (2024) · Bioengineering · doi:10.3390/bioengineering11121274 · Cited by 7
Beyond coagulation: Coagulation protease factor VIIa in cytoprotective response
Chatterjee, A., Paul, S., Mukherjee, T., Gupta, S. K., Parashar, D., Sahu, B., Kumar, U., & Das, K. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114218 · Cited by 7
New Developments in the Treatment of Intracerebral Hemorrhage
Gomes, J. A., & Manno, E. M. (2013) · Neurologic Clinics · doi:10.1016/j.ncl.2013.03.002 · Cited by 7
Nonlesional Spontaneous Intracerebral Hemorrhage
Farhat, H., Kretschmer, T., & Morcos, J. J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-5316-3.00361-0 · Cited by 8
Jiang, C. Q., Wang, J., Wang, J., & Zhang, J. (2020) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2020.105136 · Cited by 7
Acute Stroke Management in Patients Taking Dabigatran
Brouns, R., Hooff, R. V., Smedt, A. D., Moens, M., Raedt, S. D., Uyttenboogaart, M., Luijckx, G. J., Jochmans, K., & Keyser, J. D. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2012.00329.x · Cited by 7
“without improvement of clinical outcome and at a small increased risk of thromboembolic events [24, 25].”
BackgroundChakraborty, S., Stotts, G., Rush, C., Hogan, M. J., & Dowlatshahi, D. D. (2011) · Case Reports in Neurology · doi:10.1159/000330304 · Cited by 7
Appelboom, G., Piazza, M. A., Han, J. E., Bruce, S. S., Hwang, B. Y., Monahan, A., Hwang, R. Y., Kisslev, S., Mayer, S. A., Meyers, P. M., et al. (2012) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2011.10.018 · Cited by 7
“However, a phase III trial failed to show improvements in functional outcome or mortality.(4) Experts argue that randomization imbalance may explain whymost ICH trials fail to define potential new therapies.”
Self-citationCoagulation factor VIIa (recombinant) for warfarin-induced intracranial hemorrhage
Rowe, A. S., & Turner, R. M. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080478 · Cited by 7
Sadeghi, N., Kahn, D. J., Syed, D., Iqbal, O., Abro, S., Eshraghi, R., Hoppensteadt, D., & Fareed, J. (2014) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029614527496 · Cited by 7
“Mayer et al reported that rFVIIa did not improve survival or functional outcome after intracerebral hemorrhage despite the reduction in hematoma.(6) Ingerslev evaluated the efficacy and safety of rFVIIa in the prophylaxis of bleeding in various surgical procedures in patients with hemophilia having FVIII and FIX inhib…”
BackgroundState of the art in managing nontraumatic intracerebral hemorrhage
Dubourg, J., & Messerer, M. (2011) · Neurosurgical FOCUS · doi:10.3171/2011.3.focus1145 · Cited by 10
New Insights into Nonvitamin K Antagonist Oral Anticoagulants' Reversal of Intracerebral Hemorrhage
Yasaka, M. (2015) · Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences · doi:10.1159/000437116 · Cited by 7
Denetclaw, T. H., Tam, J., Arias, V., Kim, R., & Martin, C. (2015) · Journal of Pharmacy Practice · doi:10.1177/0897190015613231 · Cited by 7
Jy, W., Rehni, A. K., Bidot, C., Quero, H. N., Haase, C. R., Koch, S., Ahn, Y. S., & Dave, K. R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00599 · Cited by 7
Warrier, A. R., Bhatia, R., Garg, A. K., Srivastava, M. V. P., Dash, D., Tripathi, M., Singh, M. B., Singh, V., Vishnubhatla, S., & Prasad, K. (2020) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_183_20 · Cited by 7
“Major prognostic factors for poor outcomes in acute intracerebral hemorrhage (ICH) include baseline hematoma volume, hematoma growth, Glasgow coma scale (GCS), and presence of intraventricular hemorrhage (IVH)[1] of which hematoma growth is a potential therapeutic target.[2] Many radiological signs like Leakage sign[3…”
BackgroundSilva, Y., Diringer, M. N., Lo, B., Masjuán, J., de la Ossa, N. P., Cardinal, M., Yong, F. H., Zhu, T., Li, G., & Arkin, S. (2020) · Stroke · doi:10.1161/strokeaha.120.029789 · Cited by 7
Self-citationLee, R. P., Chaichana, K. L., Huang, J., Tamargo, R. J., & Caplan, J. M. (2020) · Current clinical neurology · doi:10.1007/978-3-030-36548-6_15 · Cited by 7
da Silva, G. R., & Furie, K. L. (2009) · Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences · doi:10.1159/000209475 · Cited by 7
Management of Intracerebral Hemorrhage In 2020
Blacker, D., & Musuka, T. D. (2011) · Future Neurology · doi:10.2217/fnl.11.49 · Cited by 7
Two Centuries of Neurology and Psychiatry in the Journal
Ropper, A. H. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1104781 · Cited by 9
Asadollahi, S., Vafaei, A., & Heidari, K. (2016) · Brain Injury · doi:10.1080/02699052.2016.1199909 · Cited by 7
Prehospital Systolic Hypertension and Outcomes in Patients with Spontaneous Intracerebral Hemorrhage
Hatcher, S. E., Chen, C., & Govindarajan, P. (2017) · Cureus · doi:10.7759/cureus.998 · Cited by 7
Beynon, C., Nofal, M., Rizos, T., Laible, M., Sakowitz, O. W., & Unterberg, A. W. (2020) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2020.07.006 · Cited by 9
[editor], D. M. (2025) · Australasian anaesthesia · doi:10.60115/11055/1305 · Cited by 7
Advances in intracerebral hemorrhage management: A comprehensive review
Wang, S., Wang, J., Elmadhoun, O., Liang, Y., & Zhao, W. (2025) · Brain Circulation · doi:10.4103/bc.bc_177_24 · Cited by 7
“[22] The lack of consistent clinical benefit in these trials may be attributed to randomization imbalances, particularly the higher proportion of patients with intraventricular hemorrhage (IVH) in the rFVIIa group, as IVH is a known determinant of poor outcomes in ICH.”
Trends in the management of atrial fibrillation: A neurologist's perspective
Hedna, V. S., Favilla, C. G., Guerrero, W. R., Patel, A., Gottipati, A., Waters, M. F., Bidari, S., & Thomas, B. (2012) · Journal of Cardiovascular Disease Research · doi:10.4103/0975-3583.102690 · Cited by 6
Andexanet alfa: trials just leave us with more questions
Buka, R. J. (2024) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2024.102628 · Cited by 6
Management of coagulation: an Australian perspective
Weightman, W. M., & Gibbs, N. M. (2011) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0b013e32834e46b1 · Cited by 6
Reversal of Oral Anticoagulants for Intracerebral Hemorrhage Patients: Best Strategies
Fuh, L., Sin, J. H., Goldstein, J. N., & Hayes, B. D. (2017) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0037-1607993 · Cited by 7
Chuck, C. C., Kim, D., Kalagara, R., Rex, N. B., Madsen, T. E., Mahmoud, L. N., Thompson, B., Jones, R. N., Furie, K. L., & Reznik, M. E. (2021) · Neurology · doi:10.1212/wnl.0000000000012856 · Cited by 6
“poor outcomes after ICH(5,17) and is one of the few potentially modifiable treatment targets in the acute setting, but the reduction of hematoma growth does not necessarily lead to improved patient outcomes.(29) In our study, we found that achieving a clinically relevant difference in outcomes required the assignment…”
BackgroundRehni, A. K., Cho, S., Zhang, Z., Khushal, P., Raval, A. P., Koch, S., Pérez‐Pinzón, M. A., Zhao, W., Jy, W., & Dave, K. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315167 · Cited by 6
“Moreover, the time taken between sICH onset and the arrival of the patient at a healthcare facility for potential therapy varies considerably [22,42].”
BackgroundConcha, M., Xu, L., Horn, M., Ohara, T., Nakamya, J., Beyer‐Westendorf, J., Shoamanesh, A., Cohen, A. T., Ladenvall, P., Connolly, S. J., et al. (2023) · Stroke Vascular and Interventional Neurology · doi:10.1161/svin.123.000997 · Cited by 7
Pensato, U., Tanaka, K., Horn, M., Teleg, E., Sultan, A. S. A., Kašičková, L., Ohara, T., Ojha, P., Marzoughi, S., Banerjee, A., et al. (2024) · European Stroke Journal · doi:10.1177/23969873241271745 · Cited by 6
Medical Versus Surgical Management of Intracerebral Hematomas
Trabert, J., & Steiner, T. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0259-7 · Cited by 6
“found decreased hematoma expansion in spontaneous ICH but could not confirm a clinical effect [39, 40].”
BackgroundSelf-citationHematoma Ventricle Distance on Computed Tomography Predicts Poor Outcome in Intracerebral Hemorrhage
Deng, L., Zhang, Y., Ji, J.-W., Yang, W., Xiao, W. L., Shen, Y., Li, R., Zhang, S., Lv, X., Li, X., et al. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.589050 · Cited by 6
“Recent studies suggested that IVH was a powerful predictor of poor clinical outcome, and reported 30-day mortality rate for patients with IVH was nearly 5 times higher than those without IVH (Tuhrim et al., 1999; Steiner et al., 2006; Mayer et al., 2008; Hanley, 2009; Hinson et al., 2010).”
ResultIn vitro characterization of CT‐001—a short‐acting factor VIIa with enhanced prohemostatic activity
Sim, D., Mallari, C. R., Teare, J. M., Feldman, R. I., Bauzon, M., & Hermiston, T. W. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12530 · Cited by 6
Contribution of Various Types of Transfusion to Acute and Delayed Intracerebral Hemorrhage Injury
Kumar, S., Andoniadis, M. M., Solhpour, A., Asghar, S., Fangman, M., Ashouri, R., & Doré, S. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.727569 · Cited by 6
Zhao, Z., Xiao, J., Wang, J., Meng, X., Li, C., Xin, T., & Li, S. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.947282 · Cited by 6
“The findings from non-surgical trials of early hemostasis and blood pressure reduction demonstrate no favorable changes in functional outcomes or mortality (Mayer et al., 2008; Anderson et al., 2013).”
BackgroundUchino, K., Pary, J. K., & Grotta, J. C. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511794568 · Cited by 11
Off‐label use of recombinant factor VIIa in two tertiary hospitals in Q ueensland
Donovan, P. J., Iedema, J., McLeod, D. S. A., Kubler, P. A., & Pillans, P. I. (2012) · ANZ Journal of Surgery · doi:10.1111/ans.12005 · Cited by 6
“0001 Platelet transfusions (units) 4 (2, 8) 4 (2, 8) 8 (1, 12) 0.”
Beynon, C., & Unterberg, A. W. (2015) · Der Unfallchirurg · doi:10.1007/s00113-015-0111-y · Cited by 6
Akutbehandlung der intrazerebralen Blutung
Sembill, J. A., & Kuramatsu, J. B. (2019) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-019-00607-9 · Cited by 8
Zou, Y., Zhang, C., Ge, H., Li, H., Fang, X., Zhong, J., Guo, P., Feng, H., & Hu, R. (2020) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2019.12.031 · Cited by 6
“Some randomized controlled trials (RCTs) have been conducted to identify the main factors that affect the outcome of ICH, such as the early diagnosis [6], hemostatic treatment [7,8], acute anti-hypertensive treatment [9], hematoma removal [10,11], etc.”
Anticoagulation reversal for intracranial hemorrhage in the era of the direct oral anticoagulants
Strein, M., May, S., & Brophy, G. M. (2020) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000706 · Cited by 6
“In addition, clinical trials demonstrate that rFVIIa does not improve survival or functional outcome after ICH [46].”
BackgroundEx vivo effect of hemostatic therapy in subarachnoid and intracerebral hemorrhage
Hvas, C. L., Lauridsen, S. V., Sandgaard, E., Gyldenholm, T., & Hvas, A. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.02.012 · Cited by 6
Spontaneous Intracerebral Hemorrhage
Dekker, S. E., Hoffer, S. A., Selman, W. R., & Bambakidis, N. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-43140-8.00022-6 · Cited by 11
Mansour, A. R., Loggini, A., Ammar, F. E., Alvarado-Dyer, R., Polster, S. P., Stadnik, A., Das, P., Warnke, P. C., Yamini, B., Lazaridis, C., et al. (2021) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2021.105996 · Cited by 6
Hemorrhage Control and Thrombosis Following Severe Injury
Zimrin, A. B., Bai, Y., Holcomb, J. B., & Hess, J. R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00040-6 · Cited by 6
Advances in Critical Care and Emergency Medicine
Mayer, S. A., & Schwab, S. (2009) · Stroke · doi:10.1161/strokeaha.108.544619 · Cited by 6
Self-citationManagement of Acquired Bleeding Problems in Cancer Patients
DeLoughery, T. G. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.03.008 · Cited by 6
Evaluation and management of stroke
Cucchiara, B. L. (2009) · Hematology · doi:10.1182/asheducation-2009.1.293 · Cited by 9
Hemorrhagic Cerebrovascular Disease
Zivin, J. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00415-2 · Cited by 6
H-Y, C. S., Xuemei, C., Konigsberg, R. G., Bresette, L. M., Galen, H., V, Sorond Farzaneh, A., & Feske, S. K. (2012) · BMC Neurology · doi:10.1186/1471-2377-12-158 · Cited by 6
“Recombinant FVIIa is able to bind to tissue factor and increase thrombin generation and platelet activation [14] at the site of hemorrhage; it is considered a possible therapeutic adjunct in life-threatening hemorrhages such as wICH and hemorrhage associated with newer oral anticoagulants.”
BackgroundResultTime is brain also counts for ICH
Rabinstein, A. A., & Anderson, C. D. (2015) · Neurology · doi:10.1212/wnl.0000000000001349 · Cited by 6
Association Between Hematoma Edema Complex and Outcomes of Primary Intracerebral Hemorrhage
Kalita, J., Kumar, D., Gupta, S. K., Pandey, P. C., Mahajan, R., & Singh, V. K. (2025) · Neurocritical Care · doi:10.1007/s12028-025-02321-1 · Cited by 5
“Early hematoma expansion has received attention because of trials on procoagulant treatment to reduce hematoma expansion [4–6].”
Aktuelle Therapieziele bei intrazerebralen Blutungen
Huttner, H. B., & Kuramatsu, J. B. (2017) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-017-0361-2 · Cited by 6
Jin, Y., Huang, Y., Chen, Y., Zhang, Y. J., Li, J., Yang, K.-C., Ye, X., Jin, L., Wu, J., Yuan, C.-Z., et al. (2023) · Stroke and Vascular Neurology · doi:10.1136/svn-2023-002439 · Cited by 6
Advances and Future Trends in the Diagnosis and Management of Intracerebral Hemorrhage
Yeager, C. E., & Garg, R. K. (2024) · Neurologic Clinics · doi:10.1016/j.ncl.2024.03.004 · Cited by 5
Heart Rate Variability and Functional Outcomes of Patients with Spontaneous Intracerebral Hemorrhage
Laichinger, K., Mengel, A., Buesink, R., Roesch, S., Stefanou, M., Single, C., Hauser, T., Krumbholz, M., Ziemann, U., & Feil, K. (2024) · Biomedicines · doi:10.3390/biomedicines12081877 · Cited by 6
“The volume of ICH was quantitatively assessed using the ABC/2 formula [29,30].”
Method'Spotting' patients at the highest risk of hematoma growth
Becker, K. J., & Tirschwell, D. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.152 · Cited by 5
Sorour, Y., van Veen, J. J., & Makris, M. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02413.x · Cited by 5
Ethics & Evidence in Medical Debates: The Case of Recombinant Activated Factor VII
Ghinea, N., Lipworth, W. L., Kerridge, I., Little, M., & Day, R. O. (2014) · The Hastings Center Report · doi:10.1002/hast.287 · Cited by 5
Timing of INR reversal using fresh-frozen plasma in warfarin-associated intracerebral hemorrhage
Akhter, M., Morotti, A., Cohen, A. S., Chang, Y., Ayres, A. M., Schwab, K. M., Viswanathan, A., Gurol, M. E., Anderson, C. D., Greenberg, S. M., et al. (2017) · Internal and Emergency Medicine · doi:10.1007/s11739-017-1680-2 · Cited by 6
“Studies suggest faster INR correction with rFVIIa [14, 38] and even reduced hematoma expansion [39, 40], but show no clear association with outcome.”
BackgroundHaemostatic treatment for intracerebral haemorrhage
Broderick, J. P. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31040-7 · Cited by 5
Self-citationStroke: Ischemic and Hemorrhagic
Boswell, K. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-28794-8_21 · Cited by 8
Chang, Z., Chu, X., Liu, Y., Liu, D., & Feng, Z. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.12.009 · Cited by 5
Metadata
- Authors
- Mayer, S. A., Brun, N. C., Begtrup, K., Broderick, J., Davis, S., Diringer, M. N., Skolnick, B. E., & Steiner, T.
- Affiliations
- Columbia University Irving Medical Center (US)
- Novo Nordisk (Denmark) (DK)
- University of Cincinnati Medical Center (US)
- The Royal Melbourne Hospital (AU)
- Washington University in St. Louis (US)
- Heidelberg University (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-15
- Volume
- 358
- Issue
- 20
- Pages
- 2127-2137
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2142640478
- Cited by
- 1,255
- References
- 29
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 44 · 2023: 36 · 2022: 38 · 2021: 75 · 2020: 71 · 2019: 57 · 2018: 59 · 2017: 75 · 2016: 60 · 2015: 68 · 2014: 77 · 2013: 90 · 2012: 105
- FWCI
- 70.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Health Sciences › Medicine › Clinical Neurology › Intracranial Aneurysms: Treatment and Complications
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- recombinant factor VIIa, intracerebral hemorrhage, hematoma expansion, hemorrhagic stroke, thromboembolic adverse events, functional outcome, modified Rankin Scale, hemostatic therapy, dose comparison, arterial events, bleeding complications, arterial thrombosis, venous thromboembolism
- MeSH terms
- Adult, Aged, Aged, 80 and over, Cerebral Hemorrhage, Double-Blind Method, Female, Hematoma, Humans, Male, Middle Aged, Recombinant Proteins, Tomography, X-Ray Computed, Glasgow Coma Scale, Factor VIIa, Treatment Failure, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.